Lucid Capital reiterates a Buy rating on BioXcel Therapeutics (BTAI) with a $15 price target after the company announced that the U.S. Patent and Trademark Office approved its patent application which covers the use of a single dose of dexmedetomidine in an oromucosal formulation for treating acute agitation in schizophrenia or bipolar patients with QT prolongation under six microseconds. Once officially granted, the patent will be eligible for inclusion in the FDA’s Orange Book as the 14th listed patent for Igalmi and is expected to expire on January 12, 2043, pending any patent term adjustments, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI:
- BioXcel Therapeutics announces patent allowance for dexmedetomidine
- BioXcel Granted Patent for Dexmedetomidine Use
- Positive Buy Rating for Bioxcel Therapeutics Driven by Promising Phase 3 Trial Developments and Valuation Alignment
- BioXcel Therapeutics reports DSMB recommends continuation of SERENITY trial
- BioXcel Therapeutics initiated with a Buy at Lucid Capital